Abatacept, nueva alternativa dentro de la familia de las terapias biológicas / Abatacept, new alternative within the family of the biological therapies
Goecke S., Annelise.
Rev. chil. reumatol
; 23(1): 12-18, 2007.
Artigo
em Espanhol
| LILACS | ID: lil-475705
T cells are key mediators of adaptive immunity that are involved in both normal and abnormal immune responses (e.g. rheumatoid arthritis). The full activation of T cells requires two signals, the antigen specific and the costimulatory signals. In the absence of costimulation, T cells that recognize the antigen either fail to respond and die or enter a state of unresponsiveness known as anergy. Thus, costimulation has become an attractive target for therapy. After a long road, in December 2005, the US Food and Drug Administration approved CTLA-Ig (Abatacept) for the treatment of rheumatoid arthritis. Abatacept is the first of a new class of drugs that selectively modulates costimulation; in this case blocking the CD28 costimulatory pathway. We review the pharmacokinetic and pharmacodynamic properties, clinical efficacy, adverse effects, and indications of abatacept.
Biblioteca responsável:
CL1.1
Texto completo
Documentos relacionados
